Preventing Gastric Glitch With Prucalopride and Buspirone: N-of-1 Clinical Trial

Sponsor
Universidade de Passo Fundo (Other)
Overall Status
Completed
CT.gov ID
NCT05377619
Collaborator
(none)
1
1
3
1.9
0.5

Study Details

Study Description

Brief Summary

Background: Gastric glitch is a new functional disease characterized by severe and transient epigastric pain occurring after challenges such as drinking alcohol and eating specific foods. Aims: In this N-of-1 trial, we first characterized the clinical and gastric tomographic images of a patient with gastric glitch highly reproducible after alcohol challenging, and then tested the effect of prucalopride and buspirone on the prevention of gastric glitch crises.

Condition or Disease Intervention/Treatment Phase
Phase 1/Phase 2

Detailed Description

Objective: To evaluate the effect of prucalopride and buspirone, compared to placebo, in the prevention of gastric pain crises, in a double-blind clinical trial of a single patient. Methods: Female, 35 years old, with signed consent to participate in the study, received 15 capsules to take 1 capsule 60 minutes before ingesting 200 ml of red wine at home (≈20 grams of alcohol), twice a week, according to her routine food, totaling 15 meals. Thus, the experimental phase lasted about eight weeks. The 15 capsules contain placebo (5 capsules), prucalopride 2 mg (5 capsules) or buspirone 10 mg (5 capsules), prepared by a specialized pharmacy in such a way that their physical characteristics do not allow the identification of which agent is being administered, neither by the patient nor the investigator controlling the trial (double-blind). The aforementioned pharmacy generated a code for each pill, randomly, and provided a sealed list with the 15 codes and their respective drugs, for disclosure after the end of the study. The patient was instructed to record in a standardized diary the occurrence of pain crises after the wine challenge, as well as their duration and intensity (Likert 0 to 10: maximum pain), and accompanying symptoms. The patient was asked to contact the researchers directly (WhatsApp) throughout the trial, to clarify any doubts or need for some assistance due to the occurrence of symptoms related to the study. The study statistics will be descriptive in terms of pain events, and the effect of the drugs will be evaluated in a statistical model suitable for the N-of-1 trial. Prucalopride is a 5-HT4 receptor agonist that accelerates gastric emptying, while buspirone is a 5-HT1A receptor agonist that enhances gastric accommodation function. The presumed pathophysiology underlying the patient's pain is retention of wine in the gastric lumen, causing pain. Stimulating gastric emptying with prucalopride or increasing the accommodation of the gastric fundus with buspirone could prevent or alleviate the pain crisis.

Study Design

Study Type:
Interventional
Actual Enrollment :
1 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
N-of-1 trial testing the effect of prucalopride, buspirone and placebo on the prevention of alcohol-induced gastric glitchN-of-1 trial testing the effect of prucalopride, buspirone and placebo on the prevention of alcohol-induced gastric glitch
Masking:
Double (Participant, Investigator)
Masking Description:
Identical capsules containing prucalopride, buspirone or placebo.
Primary Purpose:
Prevention
Official Title:
Gastric Glitch: a New Functional Disease Treated With Prucalopride and Buspirone in a N-of-1 Double-blind Clinical Trial
Actual Study Start Date :
Jan 6, 2022
Actual Primary Completion Date :
Mar 6, 2022
Actual Study Completion Date :
Mar 6, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: prucalopride

prucalopride 2 mg 1 capsule orally 1 hour before the wine challenging (during a dinner), in five dinners (2 dinners per week)

Drug: Prucalopride
prucalopride 2 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
Other Names:
  • Resolor
  • Experimental: buspirone

    buspirone 10 mg 1 capsule orally 1 hour before the wine challenging (during a dinner), in five dinners (2 dinners per week)

    Drug: Buspirone
    buspirone 10 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
    Other Names:
  • Ansitec
  • Placebo Comparator: placebo

    placebo 1 capsule orally 1 hour before the wine challenging (during a dinner), in five dinners (2 dinners per week)

    Drug: Placebo
    placebo 1 hour before the challenge with intake of wine (200 ml) and a dinner

    Outcome Measures

    Primary Outcome Measures

    1. Pain severity during gastric glitch crises [2 hours after challenging with wine intake]

      Pain severity scored by the patient using a Likert scale (1 = minimal / 10 = maximal pain) following wine intake (200 ml)

    Other Outcome Measures

    1. Occurrence of side effects secondary to tested drugs [12 hours after drugs intake]

      Registration by the patient (symptom diary) concerning the occurrence (yes/not) of side effects potentially related with prucalopride (abdominal cramps, nausea, diarrhea, and headache) and buspirone (drowsiness and dizziness) after each ethylic challange

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • adult patient suffering from severe gastric pain after ingestion of a small amount of wine
    Exclusion Criteria:
    • N/A (N-of-1 trial)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Passo Fundo Passo Fundo RS Brazil 99010-080

    Sponsors and Collaborators

    • Universidade de Passo Fundo

    Investigators

    • Principal Investigator: Fernando Fornari, University of Passo Fundo

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Fernando Fornari, Professor, Universidade de Passo Fundo
    ClinicalTrials.gov Identifier:
    NCT05377619
    Other Study ID Numbers:
    • 5.151.164
    First Posted:
    May 17, 2022
    Last Update Posted:
    May 17, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 17, 2022